Literature DB >> 25806307

Recurrence after surgery in patients with NSCLC.

Hidetaka Uramoto1, Fumihiro Tanaka1.   

Abstract

Surgery remains the only potentially curative modality for early-stage non-small cell lung cancer (NSCLC) patients and tissue availability is made possible. However, a proportion of lung cancer patients develop recurrence, even after curative resection. This review discusses the superiority of surgery, the reasons for recurrence, the timing and pattern of recurrence, the identification of factors related to recurrence, current provisions for treatment and perspectives about surgery for patients with NSCLC.

Entities:  

Keywords:  Recurrence; disease-free survival (DFS); non-small cell lung cancer (NSCLC); relapse; surgery

Year:  2014        PMID： 25806307      PMCID： PMC4367696          DOI： 10.3978/j.issn.2218-6751.2013.12.05

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


  76 in total

1.  Simple prophylactic fixation for lung torsion.

Authors:  Hidetaka Uramoto; Mitsuhiro Takenoyama; Takeshi Hanagiri
Journal:  Ann Thorac Surg       Date:  2010-12       Impact factor: 4.330

Review 2.  Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures.

Authors:  Simona Carnio; Silvia Novello; Mauro Papotti; Marco Loiacono; Giorgio Vittorio Scagliotti
Journal:  Transl Lung Cancer Res       Date:  2013-10

3.  Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.

Authors:  Matthew Koshy; Stacey A Fedewa; Renu Malik; Mark K Ferguson; Wickii T Vigneswaran; Lawrence Feldman; Andrew Howard; Khaled Abdelhady; Ralph R Weichselbaum; Katherine S Virgo
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

4.  No-touch isolation technique reduces intraoperative shedding of tumor cells into the portal vein during resection of colorectal cancer.

Authors:  N Hayashi; H Egami; M Kai; Y Kurusu; S Takano; M Ogawa
Journal:  Surgery       Date:  1999-04       Impact factor: 3.982

5.  The EMT status in the primary tumor does not predict postoperative recurrence or disease-free survival in lung adenocarcinoma.

Authors:  Yasuhiro Chikaishi; Hidetaka Uramoto; Fumihiro Tanaka
Journal:  Anticancer Res       Date:  2011-12       Impact factor: 2.480

6.  Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.

Authors:  Takayuki Kosaka; Yasushi Yatabe; Ryoichi Onozato; Hiroyuki Kuwano; Tetsuya Mitsudomi
Journal:  J Thorac Oncol       Date:  2009-01       Impact factor: 15.609

7.  Three-gene prognostic classifier for early-stage non small-cell lung cancer.

Authors:  Suzanne K Lau; Paul C Boutros; Melania Pintilie; Fiona H Blackhall; Chang-Qi Zhu; Dan Strumpf; Michael R Johnston; Gail Darling; Shaf Keshavjee; Thomas K Waddell; Ni Liu; Davina Lau; Linda Z Penn; Frances A Shepherd; Igor Jurisica; Sandy D Der; Ming-Sound Tsao
Journal:  J Clin Oncol       Date:  2007-12-10       Impact factor: 44.544

8.  DNA methylation markers and early recurrence in stage I lung cancer.

Authors:  Malcolm V Brock; Craig M Hooker; Emi Ota-Machida; Yu Han; Mingzhou Guo; Stephen Ames; Sabine Glöckner; Steven Piantadosi; Edward Gabrielson; Genevieve Pridham; Kristen Pelosky; Steven A Belinsky; Stephen C Yang; Stephen B Baylin; James G Herman
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

9.  High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.

Authors:  V Ludovini; G Bellezza; L Pistola; F Bianconi; L Di Carlo; A Sidoni; A Semeraro; R Del Sordo; F R Tofanetti; M G Mameli; G Daddi; A Cavaliere; M Tonato; L Crinò
Journal:  Ann Oncol       Date:  2009-01-19       Impact factor: 32.976

10.  Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas.

Authors:  Tetsukan Woo; Koji Okudela; Takuya Yazawa; Nobuyuki Wada; Nobuo Ogawa; Naoki Ishiwa; Michihiko Tajiri; Yasushi Rino; Hitoshi Kitamura; Munetaka Masuda
Journal:  Lung Cancer       Date:  2009-01-21       Impact factor: 5.705
View more
  143 in total

1.  Selection for adjuvant chemotherapy in completely resected stage I non-small cell lung cancer: external validation of a Chinese prognostic risk model.

Authors:  Ulas Kumbasar; Hilgardt Raubenheimer; May Al Sahaf; Nizar Asadi; Maria Elena Cufari; Chiara Proli; Periklis Perikleous; Zakiyah Niwaz; Emma Beddow; Vladimir Anikin; Niall McGonigle; Simon Jordan; George Ladas; Michael Dusmet; Eric Lim
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

2.  Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery.

Authors:  Margarita Kirienko; Luca Cozzi; Lidija Antunovic; Lisa Lozza; Antonella Fogliata; Emanuele Voulaz; Alexia Rossi; Arturo Chiti; Martina Sollini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-09-24       Impact factor: 9.236

Review 3.  Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer.

Authors:  Justin Yeh; Kristen A Marrone; Patrick M Forde
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

Review 4.  Role of epidermal growth factor receptor in lung cancer and targeted therapies.

Authors:  Tie-Cheng Liu; Xin Jin; Yan Wang; Ke Wang
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

Review 5.  miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives.

Authors:  Mateusz Florczuk; Adam Szpechcinski; Joanna Chorostowska-Wynimko
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

Review 6.  Applications and Approaches for Three-Dimensional Precision-Cut Lung Slices. Disease Modeling and Drug Discovery.

Authors:  Hani N Alsafadi; Franziska E Uhl; Ricardo H Pineda; Kolene E Bailey; Mauricio Rojas; Darcy E Wagner; Melanie Königshoff
Journal:  Am J Respir Cell Mol Biol       Date:  2020-06       Impact factor: 6.914

7.  A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.

Authors:  Elena Martínez-Terroba; Carmen Behrens; Fernando J de Miguel; Jackeline Agorreta; Eduard Monsó; Laura Millares; Cristina Sainz; Miguel Mesa-Guzman; José Luis Pérez-Gracia; María Dolores Lozano; Javier J Zulueta; Ruben Pio; Ignacio I Wistuba; Luis M Montuenga; María J Pajares
Journal:  J Pathol       Date:  2018-06-20       Impact factor: 7.996

8.  FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.

Authors:  Chang Liu; Zhi Li; Shuo Wang; Yibo Fan; Simeng Zhang; Xianghong Yang; Kezuo Hou; Jianhua Tong; Xuejun Hu; Xiaonan Shi; Xiaoxun Wang; Yunpeng Liu; Xiaofang Che; Xiujuan Qu
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-24       Impact factor: 4.553

9.  MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer.

Authors:  Duo Li; Dong-Qiong Li; Dan Liu; Xiao-Jun Tang
Journal:  Cell Oncol (Dordr)       Date:  2016-01-07       Impact factor: 6.730

10.  The prognostic impact of the mediastinal fat tissue invasion in patients with non-small cell lung cancer.

Authors:  Necati Çitak; Yunus Aksoy; Özgür İşgörücü; Ciğdem Obuz; Barış Açıkmeşe; Songül Büyükkale; Neslihan Akalın Fener; Muzaffer Metin; Adnan Sayar
Journal:  Gen Thorac Cardiovasc Surg       Date:  2020-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.